- Home
- BFST vs PRCT Comparison
BFST vs PRCT Comparison
Compare BFST & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | PRCT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.4M | 1.1B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFST | PRCT |
|---|---|---|
| Price | $31.43 | $16.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $32.75 | ★ $35.44 |
| AVG Volume (30 Days) | 251.0K | ★ 1.6M |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 23.45 | 1.71 |
| EPS | ★ 0.68 | N/A |
| Revenue | $10,704,000.00 | ★ $308,054,000.00 |
| Revenue This Year | $22.71 | $31.34 |
| Revenue Next Year | $5.02 | $24.52 |
| P/E Ratio | $44.81 | ★ N/A |
| Revenue Growth | 1.20 | ★ 37.22 |
| 52 Week Low | $22.56 | $17.17 |
| 52 Week High | $31.57 | $56.87 |
Technical Indicators
Market Signals| Indicator | BFST | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 28.06 |
| Support Level | $26.73 | N/A |
| Resistance Level | $31.49 | $29.27 |
| Average True Range (ATR) | 0.77 | 1.12 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 98.48 | 4.17 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.